Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis
- PMID: 38182488
- DOI: 10.1016/j.euo.2023.12.005
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis
Abstract
Background and objective: Although digital rectal examination (DRE) is recommended in combination with prostate-specific antigen (PSA) for detection of prostate cancer (PCa), there are limited data to support its use as a screening/early detection test. Our objective was to assess the diagnostic value of DRE in screening for early detection of PCa.
Methods: In August 2023, we queried the PubMed, Scopus, and Web of Science databases to identify prospective studies simultaneously investigating the diagnostic performance of DRE and PSA for PCa screening. The primary endpoints were the positive predictive value (PPV) and cancer detection rate (CDR) of DRE. Secondary endpoints included the PPV and CDR of both PSA alone and in combination with DRE. We conducted meta-regression analysis to compare the CDR and PPV of different screening strategies. This meta-analysis is registered on PROSPERO (CRD42023446940).
Key findings and limitations: We identified eight studies involving 85,798 participants, of which three were randomized controlled trials and five were prospective diagnostic studies, that reported the PPV and CDR of both DRE and PSA for the same cohort. Our analysis revealed a pooled PPV of 0.21 (95% confidence interval [CI] 0.13-0.33) for DRE, which is similar to the PPV of PSA (0.22, 95% CI 0.15-0.30; p = 0.9), with no benefit from combining DRE and PSA (PPV 0.19, 95% CI 0.13-0.26; p = 0.5). However, the CDR of DRE (0.01, 95% CI: 0.01-0.02) was significantly lower than that of PSA (0.03, 95% CI 0.02-0.03; p < 0.05) and the combination of DRE and PSA (0.03, 95% CI 0.02-0.04; p < 0.05). The screening strategy combining DRE and PSA was not different to that of PSA alone in terms of CDR (p = 0.5) and PPV (p = 0.5).
Conclusions and clinical implications: Our comprehensive review and meta-analysis indicates that both as an independent test and as a supplementary measure to PSA for PCa detection, DRE exhibits a notably low diagnostic value. The collective findings from the included studies suggest that, in the absence of clinical symptoms and signs, DRE could be potentially omitted from PCa screening and early detection strategies.
Patient summary: Our review shows that the screening performance of digital rectal examination for detection of prostate cancer is not particularly impressive, suggesting that it might not be necessary to conduct this examination routinely.
Keywords: Digital rectal examination; Prostate cancer; Prostate-specific antigen.
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Similar articles
-
Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.Eur Urol Oncol. 2023 Dec;6(6):566-573. doi: 10.1016/j.euo.2023.09.008. Epub 2023 Oct 6. Eur Urol Oncol. 2023. PMID: 37806841
-
Digital Rectal Exam in Prostate Cancer Screening and Elevated PSA Work-up-Is there a role anymore?Curr Urol Rep. 2024 Aug;25(8):193-199. doi: 10.1007/s11934-024-01218-4. Epub 2024 Jun 13. Curr Urol Rep. 2024. PMID: 38869693 Review.
-
The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.J BUON. 2015 Nov-Dec;20(6):1601-5. J BUON. 2015. PMID: 26854458
-
Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14. BJU Int. 2012. PMID: 22892057
-
Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.J Natl Med Assoc. 2006 Apr;98(4):492-504. J Natl Med Assoc. 2006. PMID: 16623061 Free PMC article. Review.
Cited by
-
Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool.Appl Clin Inform. 2024 Mar;15(2):282-294. doi: 10.1055/s-0044-1782619. Epub 2024 Apr 10. Appl Clin Inform. 2024. PMID: 38599619 Free PMC article.
-
Association between the use of proton pump inhibitors and serum PSA levels in the general U.S. population.World J Urol. 2025 Feb 21;43(1):133. doi: 10.1007/s00345-025-05469-9. World J Urol. 2025. PMID: 39982526 Free PMC article.
-
Predicting the Diagnosis of Prostate Cancer with a Novel Blood-Based Biomarker: Comparison of Its Performance with Prostate-Specific Antigen.Cancers (Basel). 2024 Jul 23;16(15):2619. doi: 10.3390/cancers16152619. Cancers (Basel). 2024. PMID: 39123347 Free PMC article.
-
Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study.World J Mens Health. 2025 Apr;43(2):282-290. doi: 10.5534/wjmh.240081. Epub 2024 Aug 2. World J Mens Health. 2025. PMID: 39344109 Free PMC article. Review.
-
De novo small cell neuroendocrine prostate cancer: An atypical case presentation.Urol Case Rep. 2025 Feb 4;59:102970. doi: 10.1016/j.eucr.2025.102970. eCollection 2025 Mar. Urol Case Rep. 2025. PMID: 40051833 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous